EFFICACY AND SAFETY OF LONG-TERM CONTINUOUS EXPOSURE TO CERTOLIZUMAB PEGOL OVER 3.5 YEARS IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE PRECISE 3 MAINTENANCE STUDY

(1) Christian Albrechts University, Kiel, Germany

(2) Department of Medicine, University of Pennsylvania School of Medicine, Pennsylvania, United States

(3) Department of Gastroenterology, University of Copenhagen, Copenhagen, Denmark

(4) University of Western Australia, Fremantle Hospital, Fremantle, Australia

(5) Department of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, United States

(6) Biostatistics, UCB, Slough, United Kingdom

(7) Division of Gastroenterology and Hepatology, Mayo Clinc, Rochester, United States



This item was part of the IMMFLAMMATORY BOWEL DISEASE III session at Gastro 2009 UEGW/WCOG London (17th UEGW)

This item can be cited as: Gut 2009; 58 (Suppl II) A469